Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aileron Therapeutics Inc ALRN

Healthcare Biotechnology
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib... see more

Recent & Breaking News (NDAQ:ALRN)

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

PR Newswire November 14, 2024

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

PR Newswire November 13, 2024

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma

PR Newswire October 31, 2024

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

PR Newswire October 12, 2024

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

PR Newswire September 23, 2024

Aileron Therapeutics to Present at the 8th Annual IPF Summit

PR Newswire August 19, 2024

Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

PR Newswire August 14, 2024

Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

PR Newswire July 30, 2024

Aileron Therapeutics to be Included in the Russell Microcap® Index

PR Newswire July 1, 2024

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire May 15, 2024

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire May 6, 2024

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

GlobeNewswire May 3, 2024

Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

GlobeNewswire May 1, 2024

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

GlobeNewswire May 1, 2024

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire April 15, 2024

Aileron Therapeutics Announces CEO Transition

GlobeNewswire March 12, 2024

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

GlobeNewswire February 15, 2024

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

GlobeNewswire February 1, 2024

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

PR Newswire October 31, 2023

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

GlobeNewswire February 21, 2023